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Clinical outcomes included number of ADEs (deep vein throm-
bosis, pulmonary embolism, stroke, bleeding, or hemorrhage)
number of PT/INR measurements after warfarin initiation, and
proportion of time spent within PT/INR range. Economic out-
comes included health care utilization and medical or pharmacy
costs. RESULTS: The Incidence Rate Ratio (IRR) for all ADEs
after warfarin initiation was 0.55 (95% CI 0.44–0.68) for the
intervention group as compared to control. Number of strokes
(IRR 0.61, 95% CI 0.39–0.94) and number of bleeding episodes
(IRR 0.59, 95% CI 0.44–0.79) were also signiﬁcantly reduced
for the intervention group. Mean proportion of time within the
therapeutic PT/INR range was 37% in the intervention group
and 31% in the control group (P = 0.0003). Economic outcomes
were not signiﬁcantly different between groups. CONCLU-
SIONS: This mail-based warfarin education program is associ-
ated with a decreased number of ADEs and an increased
proportion of time within the therapeutic PT/INR range.
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OBJECTIVES: Study objectives were to assess the impact of 
celecoxib, rofecoxib, or naproxen on blood pressure and BP 
goal attainment in a veteran population. Secondary objectives
included assessment of associated cardiovascular risk, and
changes to other medications associated with study drug use.
METHODS: Computerized medical and prescription records
were used to identify 262 consecutive patients receiving a new
prescription for rofecoxib, celecoxib or naproxen, from January
2001 to October 2005. Data collected in eligible patients
included patient demographics; drug utilization information for
the study drug and concomitant antihypertensives; baseline and
follow-up laboratory and clinical data including BP, and lipid
panel information. Inclusion criteria included age >49, treatment
with study drug for at least two weeks (not PRN), and stabi-
lization of preexisting antihypertensives for at least 30 days, for
hypertensive patients. Exclusion criteria included lack of follow-
up information or death prior to study completion, and/or use
of any of the following: MAO-inhibitors; tricyclic antidepres-
sants; sympathomimetics; glucocorticoids; corticotropin;
cyclosporine; oral contraceptives; concomitant NSAID’s (includ-
ing >325mg/day of aspirin). Statistical analysis was conducted
using the Chi-square test for demographic data. Intra-group
comparisons were analyzed using the paired student’s t-test,
while intra-group differences were assessed by analysis of vari-
ance. RESULTS: Analysis revealed signiﬁcant BP reduction in
celecoxib patients (-7/-5mmHg, p < 0.01). BP change was not
observed in naproxen patients, while BP increase was observed
in rofecoxib patients (+5/+2mmHg, p < 0.05). A majority of cele-
coxib patients were switched from an alternate therapy (60%
from rofecoxib, 9% from NSAID), while only 29% and 12% of
rofecoxib and naproxen patients were switched. BP reduction
was associated with improvement in JNC-VII stage in 47% of
celecoxib patients (p < 0.01), who were hypertensive (BP >
140/90) at treatment onset (47.5%). CONCLUSION: Clinically
relevant BP reduction may be an additional beneﬁt of celecoxib
in hypertensive patients requiring treatment with NSAID.
CARDIOVASCULAR DISEASE—Cost Studies
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The antiplatelet clopidogrel is widely recommended in acute
coronary syndrome (ACS), however, most cost evaluations of
this therapy originate from the clinical trial environment.
OBJECTIVES: This study compared medical costs in the usual
care setting between clopidogrel and non-clopidogrel recipients
following an ACS event. METHODS: Administrative claims
data from a large U.S. health plan (from Janaury 1, 2001–June
30, 2003) were used to identify patients with ACS by ICD-9
codes for unstable angina or acute myocardial infarction; the ﬁrst
diagnosis claim was the “index event.” Patient groups were those
who received clopidogrel ≤15 days of an index event versus those
who did not. They were observed 1-year before, and followed
up to 1-year after, the index event. The primary endpoint was
medical costs during follow-up. Propensity score matching was
used to identify closely matched patient groups. Controlling for
confounding demographic and clinical characteristics, patients
were matched based on propensity to receive clopidogrel. Due
to variable follow-up periods, censored regression analysis was
used to compare costs; step one used a logistic regression model
to estimate the probability of not being censored; step two used
the inverse of this probability as a weight in the generalized linear
model (GLM). RESULTS: Propensity score matching identiﬁed
2826 patients (1413 in each group). Mean age was 58 years;
68% were male. The logistic regression indicated clopidogrel
patients had shorter follow-up periods. The weighted GLM indi-
cated monthly follow-up cardiovascular costs were 53% lower
and monthly follow-up all medical costs were 56% lower, for
clopidogrel versus non-clopidogrel patients (p < 0.05 for all com-
parisons). CONCLUSION: Patients who received clopidogrel
≤15 days from an ACS event had lower follow-up medical costs
compared to patients who did not receive clopidogrel. These data
provide additional economic support in the usual care setting for
clopidogrel treatment after ACS.
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